Skip to main content

Table 3 Exposure. Values are number (percentage) unless otherwise indicated

From: Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties

Prednisolone 214 (43.3)
Prednisolone, dose mg/d, mean (valid no 489) 5.5
Number of ongoing DMARDs1
 0 109 (22.1)
 1 243 (49.2)
 2 132 (26.7)
 3 10 (2)
cDMARD2 343 (69.4)
Methotrexate 274 (55.5)
Methotrexate dose, mg/w, mean (valid no 488) 16
cDMARD2 other than methotrexatea 69 (14)
bDMARD3 193 (39.1)
TNF- alpha inhibitorb 157 (31.8)
bDMARD3, other than TNF- alpha inhibitorc 36 (7.3)
Methotrexate and prednisolone 124 (25.1)
Methotrexate and TNF- alpha inhibitor 90 (18.2)
Methotrexate and prednisolone and TNF- alpha inhibitor 40 (8.1)
  1. 1 Disease-modifying antirheumatic drug
  2. 2 Conventional disease-modifying antirheumatic drug
  3. 3 Biologic disease-modifying antirheumatic drug
  4. a azathioprine (n = 9), sulfasalazine (n = 30), hydroxychloroquine (n = 26), mycophenolate mofetil (n = 3) and leflunomide (n = 1)
  5. betanercept (n = 93), golimumab (n = 5), certolizumab (n = 12), infliximab (n = 15), adalimumab (n = 32)
  6. c abatacept (n = 6), rituximab (n = 16), anakinra (n = 5), tocilizumab (n = 14) One patient did bilateral THA at the same session and was treated with both anakinra and rituximab